Moxalactam (Moxam,Eli Lilly)

Wise R Wright N Wills P . In vitro and pharmacological properties of the epimers of moxalactam. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Moxalactam package insert. Eli Lilly and Co., Sept 30, 1981.

Curtis N Brown C Boxall M Boulton M . Inhibition of Escherichia coli K-12 by β-lactam antibiotics with poor antibacterial activity: Interaction of permeability and intrinsic activity against penicillin-binding proteins. Antimicrob Agents Chemother 1979; 15: 332–6.

Yoshida T Matsuura S Mayama M Kemeda U Moxalactam Kuwahara S. (6059S), a novel 1-oxa-β-lactam with an expanded antibacterial spectrum: Laboratory evaluation. Antimicrob Agents Chemother 1980; 17: 302–12.

Murakami K Yoshida T . Role of the 7α-methoxy and side-chain carboxyl of moxalactam in β-lactamase stability and antibacterial activity. Antimicrob Agents Chemother 1981; 19: 1–7.

Hall W Opfer B . Correlation of moxalactam (LY127935) susceptibility tests by disc diffusion and agar plate dilution methods. Antimicrob Agents Chemother 1981; 19: 130–3.

Fass R . In vitro activity of LY127935. Antimicrob Agents Chemother 1979; 16: 503–9.

Weaver S LeBlanc B Bodey G . In vitro studies of 1-oxa-cephalosporin (LY127935), a new beta-lactam antibiotic. Antimicrob Agents Chemother 1980; 17: 92–5.

Barza M Talley F Jacobus N Gorbach S . In vitro activity of LY127935. Antimicrob Agents Chemother 1979; 16: 287–92.

Trager G White G Zimelis V Panwalker A . LY127935: A novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother 1979; 16: 297–300.

Hall W Opfer B Gerding P . Comparative activities of the oxa-β-lactam LY127935, cefotaxime, cefoperazone, cefamandole and ticarcillin against multiple resistant gram-negative bacilli. Antimicrob Agents Chemother 1980; 17: 273–9.

Eickhoff T Ehret J . Comparative in vitro studies of R013-9904, a new cephalosporin derivative. Antimicrob Agents Chemother 1981; 19: 435–42.

Wise R Andrews J Bedford K . LY127935, a novel oxa-β-lactam: An in vitro comparison with other β-lactam antibiotics. Antimicrob Agents Chemother 1979; 16: 341–5.

Pulliam L Hadley W Mills J . In vitro comparison of third-generation cephalosporins, piperacillin, dibekacin, and other aminoglycosides against aerobic bacteria. Antimicrob Agents Chemother 1981; 19: 490–2.

Verbist L Verhagen J . In vitro activity of N-formimodyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother 1981; 19: 402–6.

DeMaria A Alvarez S Klein J McCabe W . In vitro studies of moxalactam (LY127935), a new beta-lactam antibiotic with significant activity against gram-negative bacteria. Infection 1980; 8: S261–7.

Verbist L . Comparison of in vitro activities of eight β-lactamase stable cephalosporins against β-lactamase producing gram-negative bacilli. Antimicrob Agents Chemother 1981; 19: 407–13.

Lang S Edwards D Durach D . Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli. Antimicrob Agents Chemother 1980; 17: 488–93.

Barry A Thornsberry C Jones R . In vitro evaluation of LY127935 (6059S) compared with cefotaxime, eight other β-lactams and two aminoglycosides. J Antimicrob Chem 1980; 6: 775–84.

Moxalactam (editorial). Lancet 1981; 2: 23–4.

Livingston W Elliott A Cobbs C . In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens and Enterococcus sp. Antimicrob Agents Chemother 1981; 19: 114–6.

Reimer L Mirrett S Reller L . Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin and ticarcillin against 420 blood culture isolates. Antimicrob Agents Chemother 1980; 17: 412–6.

Yu V Vickers R Zuravleff J . Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY127935) and eight other antipseudomonal antimicrobial agents (old and new). Antimicrob Agents Chemother 1980; 17: 96–8.

Borobio MV Aznar J Jimenez R Garcia F Perea E . Comparative in vitro activity of 1-oxa-β-lactam (LY127935) and cefoperazone with other β-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother 1980; 17: 129–31.

Jorgensen J Crawford S Alexander G . Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria. Antimicrob Agents Chemother 1980; 17: 901–4.

Marrie T Haldane E Swantee C Kerr E . Susceptibility of anaerobic bacteria to nine antimicrobial agents and demonstration of decreased susceptibility of Clostridium perfringens to penicillin. Antimicrob Agents Chemother 1981; 19: 51–5.

Brown J Del Bene V Collins C . In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new β-lactam agents against Bacteroides fragilis: contribution of β-lactamase to resistance. Antimicrob Agents Chemother 1981; 19: 248–52.

Nasu M Maskell J Williams R Williams J . In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides sp. Antimicrob Agents Chemother 1981; 20: 433–6.

Prince A Neu H . Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother 1981; 20: 545–6.

Ellner P Neu HC . The inhibitory quotient—a method for interpreting minimum inhibitory concentration data. JAMA 1981; 246: 1575–8.

Mintz L Drew L . Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam and carbenicillin, combined with tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1981; 19: 332–4.

Kurtz T Winston D Bruckner D Martin W . Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens. Antimicrob Agents Chemother 1981; 20: 234–43.

Parsons J Romano J Levison M . Pharmacology of a new 1-oxa-β-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother 1980; 17: 226–8.

Srinivasan S Fu K Neu H . Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. Antimicrob Agents Chemother 1981; 19: 302–5.

Scheld W Spyker D Donowitz G Bolton W Sande M . Moxalactam and cefazolin: Comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother 1981; 19: 613–9.

Wise R Baker S Livingston R . Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother 1980; 18: 369–71.

Standiford H . Comparative pharmacokinetics of moxalactam, cefoperazone and cefotaxime in normal volunteers. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Polk R Kline B Markowitz S . Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. Antimicrob Agents Chemother 1981; 20: 576–9.

Leitinger E Polk R . Comparative pharmacokinetics of moxalactam and cefoxitin in normal volunteers. Manuscript in preparation.

Axelrod JL Kochman RS . Moxalactam (LY127935) penetration into human aqueous humor. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 22–24, 1980, New Orleans (abstract 245).

Polk R Hume A Cardea J . Comparative bone penetration of moxalactam and cefazolin following simultaneous administration. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 736).

Polk R Smith Ducey K. Lower R . Atrial appendage penetration of moxalactam and cefazolin after simultaneous im or iv administration. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 734).

Stephens N Kronfol N Polk R . Peritoneal absorption of moxalactam in patients with peritonitis. 16th Annual Meeting of the American Society of Hospital Pharmacists, Dec 6–10, 1981, New Orleans (abstract 245).

Smith R Sutphen N Baltch A Wilbur H Conroy J Hammer M . Moxalactam penetration into human prostate tissue. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 737).

Preheim L McCracken G Jubelirer P Sanders C Barrett F . Moxalactam penetration into brain abscess. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 738).

Mouton Y Caillan M Beaucaire G Fourrier A . Penetration of moxalactam in bronchial secretions and clinical evaluation in intensive care patients. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 732).

Martinez OV Levi JU Livingstone A . Biliary excretion of moxalactam. Antimicrob Agents Chemother 1981; 20: 231–4.

Workman M Duma R Baggett J Polk R Shadomy S Espinel-Ingroff A . Study of pharmacology of moxalactam (LY127935) in human cerebrospinal fluid. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 735.)

Landesman S Corrado M Cherubin C Gombart M Cleri D . Diffusion of a new beta-lactam (LY127935) into cerebrospinal fluid—implications for therapy of gram-negative bacillary meningitis. Am J Med 1980; 69: 92–7.

Olson D Hoeprich P Nolan S Goldstein E . Successful treatment of gram-negative bacillary meningitis with moxalactam. Ann Intern Med 1981; 95: 302–5.

Landesman S Corrado M Shah P Armengand M Barza M Cherubin C . Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis. Am J Med 1981; 71: 693–703.

Schaad U McCracken G Loock C Thomas M . Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin and ampicillin in experimental gram-negative enteric bacillary meningitis. Antimicrob Agents Chemother 1980; 17: 406–11.

Schaad U McCracken G Loock C Thomas M . Pharmacokinetics and bacteriological efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental meningitis. J Infect Dis 1981; 143: 156–63.

Sande MA . Antibiotic therapy of bacterial meningitis: Lessons we've learned. Am J Med 1981; 71: 507–10.

Peterson L Bean B Fasching C Korchik W Gerding D . Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects. Antimicrob Agents Chemother 1981; 20: 378–81.

Shimada J . 6059S: Absorption, excretion, distribution and metabolism. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Bolton W Scheld W Spyker D Overby T Sandy M . Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother 1980; 18: 933–8.

Lam M Manion C Czerwinshi A . Pharmacokinetics of moxalactam in patients with renal insufficiency. Antimicrob Agents Chemother 1981; 19: 461–4.

Srinivasan S Neu H . Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis. Antimicrob Agents Chemother 1981; 20: 398–400.

Aronoff G Sloan R Mong S Luft F Kleit S . Moxalactam pharmacokinetics during hemodialysis. Antimicrob Agents Chemother 1981; 19: 575–7.

Hewitt W McHenry M . Blood level determinations of antimicrobial drugs. Med Clin North Am 1978; 62: 1119–40.

Stone H Haney B Kolb L Geheber C Morris E . Clinical comparison of moxalactam versus a combination gentamicin-clindamycin in peritoneal and soft tissue sepsis. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 22–24, 1980, New Orleans (abstract 248).

Murphy TF Barza M . Treatment of intra-abdominal infection with moxalactam. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Busuttil R McGrattan M Winston D . Moxalactam therapy for the treatment of intraabdominal sepsis. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Rambo W Del Bene V . Moxalactam compared with clindamycin/aminoglycoside in common surgical infections. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Cordera C Peharek R . Treatment of experimental Haemophilus influenzae type b meningitis with 1-oxa-β-lactam (LY127935). Antimicrob Agents Chemother 1980; 17: 258–62.

Rahal J . Accumulated experience with moxalactam therapy of gram-negative bacillary meningitis. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Oblinger M Bowers J Sande M Mandell J . Moxalactam vs. standard antimicrobial therapy for serious infections. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Livingston W Elliott A Dismukes W Avent C Cobbs C . Clinical evaluation of moxalactam. Antimicrob Agents Chemother 1981; 20: 88–97.

Tofte R Rothschafer J Solliday J Crossley K . Moxalactam therapy for a wide spectrum of bacterial infections in adults. Antimicrob Agents Chemother 1981; 19: 740–4.

Trager G Panwalker A Malow J Porembski P Ramirez C Zar F . Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal disease. Chemotherapy 1981; 27: 287–95.

Lentino J Rytel M Moore E . Therapy of lower respiratory tract infections with moxalactam. Antimicrob Agents Chemother 1981; 19: 801–6.

Perlino C . Moxalactam therapy of bacterial pneumonia. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Mader J Stovall J . Treatment of chronic osteomyelitis with moxalactam. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 319).

Platt R Ehrilich S Afarian J O'Brien T Pennington J Kass E . Moxalactam therapy of infections caused by cephalothin-resistant bacteria: Influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother 1981; 20: 351–5.

Winston DJ Busuttil RW Kurtz T Young L . Moxalactam therapy for bacterial infections. Arch Intern Med 1981; 141: 1607–12.

Wilson W Key ST Mueller S Anhalt J . Moxalactam therapy of septicemia. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 316).

Fainstein V Elting L Bolivar R Bodey G . Moxalactam and ticarcillin or tobramycin for the treatment of neutropenic cancer patients. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 317).

Cunningham F Hemsell D Depalma R Kappus S Roark M Nobles B . Moxalactam for obstetric and gynecologic infections: In vitro and dose-finding studies. Am J Obstet Gynecol 1981; 139: 915–21.

Gibbs R Blanco J Castaneda Y St. Clair P . Therapy of obstetrical infections with moxalactam. Antimicrob Agents Chemother 1980; 17: 1004–7.

Yu V . Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med 1981; 94: 784–5.

Lentnek A . Enterococcal suprainfection in patients treated with moxalactam. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 325).

Preheim LC Penn RG Sanders C Goering R . Emergence of resistance to moxalactam and aminoglycosides with moxalactam therapy of Pseudomonas infections. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4–6, 1981, Chicago (abstract 729).

Kammer R . Moxalactam clinical summary—efficacy and safety. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Rymer W Greenlaw C . Hypoprothrombinemia associated with cefamandole. Drug Intell Clin Pharm 1980; 14: 780–3.

Holt R Gorrochategui M Perez C . Hypoprothrombinemia associated with moxalactam treatment of a septic sternoclavicular arthritis due to Citrobacter diversus. Drug Intell Clin Pharm 1981; 15: 288–9.

Bang N Tessler S Heidenreich R Marks C Mattler L . Effects of moxalactam on blood coagulation and platelet function. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Neu HC Prince A . Interaction between moxalactam and alcohol. Lancet 1980; 1: 1422.

Wold J Buening M . Alcohol-moxalactam interactions in-vivo. Symposium on the New Generation of Beta-Lactam Antibiotics, May 7–8, 1981, London, England.

Tofte R . Antibiotic-associated colitis during moxalactam therapy. J Antimicrob Chem 1981; 7: 445–6.